Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer

被引：0
|
作者：
Barnato, Sara E.
Jeruss, Jacqueline Sara
Bethke, Kevin P.
Hansen, Nora M.
Khan, Seema Ahsan
Von Roenn, Jamie H.
Rosen, Steven T.
Gradishar, William John
Siziopikou, Kalliopi P.
Meservey, Caitlin
Kaklamani, Virginia G.
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
[2] Lynn Sage Comprehens Breast Ctr, Chicago, IL USA
[3] Lynn Sage Comprehens Canc Ctr, Chicago, IL USA
[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1134
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I/IB trial of eribulin and everolimus in patients with triple-negative metastatic breast cancer.
    Luu, Thehang H.
    Blanchard, Suzette
    Yim, John Hosei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
    Liu, Jieqiong
    Wang, Ying
    Tian, Zhenluan
    Lin, Ying
    Li, Hengyu
    Zhu, Zhaowen
    Liu, Qiang
    Su, Shicheng
    Zeng, Yinduo
    Jia, Weijuan
    Yang, Yaping
    Xu, Shengqiang
    Yao, Herui
    Jiang, Wen
    Song, Erwei
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [23] Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
    Jieqiong Liu
    Ying Wang
    Zhenluan Tian
    Ying Lin
    Hengyu Li
    Zhaowen Zhu
    Qiang Liu
    Shicheng Su
    Yinduo Zeng
    Weijuan Jia
    Yaping Yang
    Shengqiang Xu
    Herui Yao
    Wen Jiang
    Erwei Song
    Nature Communications, 13
  • [24] Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate
    Braeutigam, Karen
    Mitzlaff, Katharina
    Uebel, Lisa
    Koester, Frank
    Polack, Stephan
    Pervan, Mascha
    Steinert, Gunnar
    Rody, Achim
    Liedtke, Cornelia
    ANTICANCER RESEARCH, 2016, 36 (06) : 2759 - 2766
  • [25] A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)
    Obeid, E.
    Miller, K. D.
    Sparano, J. A.
    Blackwell, K.
    Goldstein, L. J.
    CANCER RESEARCH, 2017, 77
  • [26] Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer.
    Singh, Jasmeet Chadha
    Stein, Stacy
    Volm, Matthew
    Smith, Julia Anne
    Novik, Yelena
    Speyer, James L.
    Meyers, Marlene
    Adams, Sylvia
    Omene, Coral Oghenerukevwe
    Muggia, Franco
    Schneider, Robert
    Formenti, Silvia
    Davis, Samantha
    Beardslee, Brian
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Efficacy of neoadjuvant systemic carboplatin therapy in triple-negative breast cancer
    Thomssen, Christoph
    Schuler, Kathleen
    Bauer, Marcus
    Reinhardt, Kristin
    Strauss, Hans-Gerorg
    Vetter, Martina
    CANCER RESEARCH, 2022, 82 (04)
  • [28] The East Carolina Breast Center phase II trial of neoadjuvant metronomic chemotherapy in triple-negative breast cancer
    Raab, R. E.
    Walker, P. R.
    Bellin, L. S.
    Wong, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Triple-negative Breast Carcinoma: Carboplatin and Veliparib in the Neoadjuvant
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2018, 78 (07)
  • [30] A phase II trial of docetaxel plus carboplatin plus bevacizumab as neoadjuvant therapy for triple negative breast cancer
    Chacon Lopez-Muniz, J. I.
    Cardenas, J. D.
    Santos Rodriguez, A. K.
    Esteban Esteban, M. C.
    Munoz Platon, E.
    Rubio Salvador, A. R.
    Alonso Soler, S. E.
    Fernandez Franco, L.
    San Juan del Moral, A.
    Burgueno Lorenzo, I.
    Trujillo Alba, B. L.
    Martinez Moreno, E.
    Moya Gomez, P.
    Cruz Mora, M. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S283 - S283
12345